Metronomic Effect as A New Hypothesis in Maintenance Therapy of Acute Lymphoblastic Leukemia
author
Abstract:
This article doesn't have abstract
similar resources
metronomic effect as a new hypothesis in maintenance therapy of acute lymphoblastic leukemia
0
full textMetronomic Maintenance Therapy in Refractory Acute Myeloblastic Leukemia with Monosomy 7
Patients with acute myeloblastic leukemia (AML) with monosomy 7 are a group of patients with refractory AML who have a very poor prognosis. Therefore, rationally designed new therapies, including metronomic chemotherapy regimen with histidine deacetylase inhibitors (Valporic acid, ATRA) are being investigated as potential treatments for the population of refractory cases of AML. Herein, we repo...
full textassessment of the effect of honey as a topical therapy for intra oral wound healing in rat.
چکیده ندارد.
15 صفحه اولUBE2Q1, as Down Regulated Gene in Pediatric Acute Lymphoblastic Leukemia
Ubiquitin - proteasome system (UPS), the major protein degradation pathway in the cells, typically degrades short - lived and damaged proteins and regulates growth and stress responses. This pathway is altered in various cancers, including Acute Lymphoblastic Leukemia (ALL). ALL begins with a change in bone marrow cells and is the most common type of leukemia in children under 15 years. UBE2Q1...
full textmetronomic maintenance therapy in refractory acute myeloblastic leukemia with monosomy 7
patients with acute myeloblastic leukemia (aml) with monosomy 7 are a group of patients with refractory aml who have a very poor prognosis. therefore, rationally designed new therapies, including metronomic chemotherapy regimen with histidine deacetylase inhibitors (valporic acid, atra) are being investigated as potential treatments for the population of refractory cases of aml. herein, we repo...
full textRituximab as therapy for acute lymphoblastic leukemia.
DT Frontline treatment approaches for newly diagnosed ALL have evolved from “one size fits all” chemotherapy regimens to subtype-oriented chemotherapy programs. The traditional risk factors that influence selection of therapy primarily include characteristics of the host, such as age, and features of the disease, such as lineage (T-lymphoblastic, B-lymphoblastic, or Burkitt-type [mature B-cell]...
full textMy Resources
Journal title
volume 8 issue None
pages 88- 89
publication date 2016-09
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023